Shoals Technologies Group, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call

PORTLAND, Tenn., April 07, 2025 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (the “Company”) (Nasdaq: SHLS) today announced that the Company will release its first quarter 2025 results before market open on Tuesday, May 6, 2025, to be followed by a conference call at 8:00 a.m. (Eastern Time) on the same day.

Interested investors and other parties can access the live webcast through the Investor Relations section of the Company’s website at https://investors.shoals.com. An archived replay of the webcast will be available shortly after the event concludes.

About Shoals Technologies Group, Inc.

Shoals Technologies Group is a leading provider of electrical balance of systems (“EBOS”) solutions for the energy transition market. Since its founding in 1996, the Company has introduced innovative technologies and systems solutions that allow its customers to substantially increase installation efficiency and safety while improving system performance and reliability. Shoals Technologies Group is a recognized leader in the renewable energy industry. For additional information, please visit: https://www.shoals.com.

Contacts:

Investor Relations:

Matt Tractenberg, VP of Finance and Investor Relations
Email: [email protected]

Media:

Lindsey Williams, VP of Marketing and Communications
Email: [email protected]



Cinemark Crafts All-Time Domestic Box Office Record for a Three-Day Family Film Opening Weekend as A Minecraft Movie Shines Like a Beacon in Theaters

Cinemark Crafts All-Time Domestic Box Office Record for a Three-Day Family Film Opening Weekend as A Minecraft Movie Shines Like a Beacon in Theaters

Film also secured the exhibitor’s highest-grossing D-BOX motion seats weekend ever.

PLANO, Texas–(BUSINESS WIRE)–Cinemark Holdings, Inc., one of the largest and most influential theatrical exhibition companies in the world, achieved an all-time-high three-day domestic opening weekend for a PG-rated film as A Minecraft Movie brought mobs of moviegoers to theaters across the nation. Big screens delighted movie fans, serving as portals to a new world, notching industry-wide videogame adaptation records. In addition to its massive Cinemark box office record, the film also generated the Company’s highest grossing D-BOX motion seats weekend ever.

“Cinemark auditoriums were packed with enthusiastic fans as A Minecraft Movie built a must-see-on-the-big-screen experience for moviegoers of all ages, driving an all-time family film record as well as best-ever D-BOX motion seat ticket sales weekend for our company,” said Sean Gamble, Cinemark President & CEO. “After an exhilarating week with our fellow exhibitors and studio partners at CinemaCon, we are thrilled to see further validation that movie theaters provide positive, shared entertainment, build community, and meaningfully amplify the wonder and excitement of captivating stories. Congratulations to everyone at Warner Bros. Discovery for delivering such a fantastic film and thank you to the Cinemark team for serving so many excited guests.”

The cinematic momentum will continue throughout the year and beyond as more compelling content is delivered to the silver screen. Moviegoers will be treated to a thrilling slate throughout this spring and summer with consecutive highly anticipated releases including Sinners on April 18, The Accountant 2 on April 25, Thunderbolts* on May 2, Final Destination: Bloodlines on May 16, Mission: Impossible – The Final Reckoning and Lilo & Stitch on May 23, Karate Kid: Legends on May 30, Ballerina on June 6, How to Train Your Dragon on June 13, Elio on June 20, F1 on June 27, Jurassic World Rebirth on July 2, Superman on July 11, The Fantastic Four: First Steps on July 25 and so much more. Later in the year, multiple notable titles are set to delight movie lovers including Freakier Friday on August 8, Tron: Ares on October 10, Wicked: For Good on November 21, Zootopia 2 on November 26, Five Nights at Freddy’s 2 on December 5, and Avatar: Fire and Ash on December 19 to name a few.

Alongside the sight and sound technology that cannot be replicated at home, Cinemark gives moviegoers the star treatment with its fan-favorite loyalty program, convenient concessions ordering and online merchandise store. Cinemark Movie Rewards awards movie lovers with one point for every dollar spent at a Cinemark theater, and fans can level up to Cinemark Movie Club, a monthly membership program with star-studded benefits such as a monthly movie credit with no rollover and no expiration, a 20 percent discount on concessions and more. Snacking has never been easier at Cinemark, with advanced mobile ordering for easy pick up within the theater and third-party delivery partnerships with DoorDash, Grubhub and Uber Eats, to ensure customers can enjoy their favorite movie theater concessions whenever and wherever the craving hits. And shop.cinemark.com makes it simple for super fans to purchase great movie merchandise at any time.

For full details about the Cinemark moviegoing experience, visit Cinemark.com or download the Cinemark app. Click HERE for general Cinemark images and b-roll.

About Cinemark Holdings, Inc.

Cinemark Holdings, Inc. (NYSE: CNK) provides extraordinary out-of-home entertainment experiences as one of the largest and most influential theatrical exhibition companies in the world. Based in Plano, Texas, Cinemark makes every day cinematic for moviegoers across nearly 500 theaters and more than 5,500 screens, operating in 42 states in the U.S. (304 theaters; 4,255 screens) and 13 South and Central American countries (193 theaters; 1,398 screens). Cinemark offers guests superior sight and sound technology, including Barco laser projection and Cinemark XD, the world’s No. 1 exhibitor-branded premium large format; industry-leading penetration of upscale amenities such as expanded food and beverage offerings, Luxury Lounger recliners and D-BOX motion seats; top-notch guest service; and award-winning loyalty programs such as Cinemark Movie Club. All of this creates an immersive environment for a shared, entertaining escape, underscoring that there is no place more cinematic than Cinemark. For more information, visit https://ir.cinemark.com.

Cinemark Contacts:

Media:

Julia McCartha

[email protected]

Investors:

Chanda Brashears

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Food/Beverage Film & Motion Pictures Retail Other Entertainment Entertainment

MEDIA:

Logo
Logo

NRG Energy Announces Executive Leadership Change

NRG Energy Announces Executive Leadership Change

  • Rasesh Patel, President of Consumer, plans retirement; will remain in his role through the first-quarter earnings call
  • Successor expected to be appointed by the end of the second quarter

HOUSTON–(BUSINESS WIRE)–
NRG Energy Inc. (NYSE:NRG) today announced that Rasesh Patel, President, NRG Consumer, has decided to retire, effective May 19, 2025. Afterward, Mr. Patel will remain available in an advisory role to ensure a seamless transition. The Company anticipates naming a successor during the second quarter.

“Rasesh has been instrumental in executing strategic priorities and driving innovation while shaping a lasting, consumer-focused company culture. Under his leadership, we integrated our Vivint and home energy platforms to form a powerful Consumer platform, positioning NRG for long-term success,” said Larry Coben, Chair, President, and Chief Executive Officer. “While I am sorry to see him go, on behalf of the Board of Directors and all of NRG, I want to celebrate his many accomplishments, thank Rasesh for his outstanding leadership and dedication, and wish him well in his next chapter.”

Mr. Patel joined NRG in March 2023 as President of Smart Home following the acquisition of Vivint Smart Home. In March 2024, he expanded his role to lead all of NRG’s Consumer businesses, including Home Energy and Smart Home.

“Leading the integration of Smart Home and Home Energy at NRG has been an honor. We set ambitious goals and executed with focus, passion, and teamwork, delivering a smarter, cleaner, and safer home ecosystem for customers,” said Mr. Patel. “I am especially proud of our team’s dedication to pioneering the first-of-its-kind residential virtual power plant (VPP) offering—an achievement made possible by our vision of seamlessly integrating smart home technologies with energy solutions and the trusted relationships we have built with our customers.”

Mr. Patel continued, “It has been a privilege to lead and collaborate with such world-class talent in developing a scalable platform that positions NRG as the leader in the evolving energy and smart home landscape. As I step into this next chapter, I am excited to turn my focus to advisory opportunities, philanthropic work, and traveling with my wife, Suchi. I remain deeply confident in NRG’s future and its leadership in this dynamic industry. As a long-term shareholder, I look forward to witnessing NRG’s continued success in creating value for all stakeholders.”

About NRG

NRG Energy Inc. is a leading energy and home services company powered by people and our passion for a smarter, cleaner, and more connected future. A Fortune 500 company operating in the United States and Canada, NRG delivers innovative solutions that help people, organizations, and businesses achieve their goals while also advocating for competitive energy markets and customer choice. More information is available at www.nrg.com. Connect with NRG on Facebook, Instagram, LinkedIn, and X.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are subject to certain risks, uncertainties and assumptions and typically can be identified by the use of words such as “may,” “should,” “could,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “expect,” “intend,” “seek,” “plan,” “think,” “anticipate,” “estimate,” “predict,” “target,” “potential” or “continue” or the negative of these terms or other comparable terminology. Although NRG believes that the expectations are reasonable, it can give no assurance that these expectations will prove to be correct, and actual results may vary materially.

NRG undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Factors that could cause actual results to differ materially from those contemplated herein include, among others, general economic conditions; hazards customary in the power industry; the inability to execute NRG’s strategies, initiatives, or partnerships; legislative and regulatory changes; and the other risks and uncertainties detailed in NRG’s most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the SEC at www.sec.gov.

Media:

Ann Duhon 713.562.8817 [email protected]

Investors:

Brendan Mulhern 609.524.4767 [email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Other Energy Utilities Oil/Gas Coal Alternative Energy Energy Nuclear

MEDIA:

Logo
Logo

United Homes Group, Inc. Reports Preliminary 2025 First Quarter Unit Statistics

United Homes Group, Inc. Reports Preliminary 2025 First Quarter Unit Statistics

COLUMBIA, S.C.–(BUSINESS WIRE)–
United Homes Group, Inc. (the “Company”) (NASDAQ: UHG) today announced preliminary operational unit statistics for the quarter ended March 31, 2025.

The following table provides a summary of the Company’s net new orders, home starts, and home closings:

 

Three Months Ended March 31,

 

2025

 

2024

 

% Change

Net new orders

296

 

384

 

(22.9

)%

Starts

248

 

 

276

 

 

(10.1

)%

Closings

252

 

 

311

 

 

(19.0

)%

The following table provides a summary of the Company’s backlog, speculative home, and model home inventory:

 

As of March 31, 2025

 

As of March 31, 2024

 

Backlog1

 

Spec homes

 

Model homes

 

Total

 

Backlog1

 

Spec homes

 

Model homes

 

Total

Not yet started

20

 

 

 

20

 

10

 

 

 

10

Homes under construction

66

 

 

182

 

 

14

 

 

262

 

 

90

 

 

166

 

 

6

 

 

262

 

Finished homes

115

 

 

154

 

 

12

 

 

281

 

 

162

 

 

261

 

 

30

 

 

453

 

Total

201

 

 

336

 

 

26

 

 

563

 

 

262

 

 

427

 

 

36

 

 

725

 

 

% Change Period-over-Period

 

Backlog1

 

Spec homes

 

Model homes

 

Total

Not yet started

100.0

%

 

NM2

 

 

NM2

 

 

100.0

%

Homes under construction

(26.7

)%

 

9.6

%

 

133.3

%

 

(3.1

)%

Finished homes

(29.0

)%

 

(41.0

)%

 

(60.0

)%

 

(36.4

)%

Total

(23.3

)%

 

(21.3

)%

 

(27.8

)%

 

(22.1

)%

“The reduction in our net new orders was a result of unusual snow in all three of our South Carolina markets, including nearly six inches of snow in Myrtle Beach during the third week of January in addition to an industry-wide slow start to the spring selling season,” stated Interim Chief Executive Officer Jamie Pirrello. “Our January sales were unseasonably low. Sales improved in February and were much stronger in March. Sales have remained strong in the first days of April.

“Traditionally for United Homes Group, sales early each quarter translate into closings at the end of the quarter,” continued Mr. Pirrello. “The soft sales in January and early February impacted our first-quarter closings.”

Jack Micenko, President of the Company, stated, “A developing theme around our product refresh initiative has been a higher percentage of pre-sales relative to historical levels. Higher pre-sales should translate into better margins as they do not require the same level of incentives while buyer customization is typically accompanied by more option purchases.” Mr. Micenko continued, “We continue to see higher gross margins in our refreshed product set, with backlog and closed gross margins of the refreshed product trending approximately 500 basis points higher than company backlog gross margin overall. We closed 23 of these plans during the first quarter and expect the number to significantly increase as a percentage of all closings over the next few quarters.”

“The decline in finished specs year-over-year has been intentional and a result of two strategic initiatives,” shared the Company’s Chief Financial Officer Keith Feldman. “First, we are more actively managing the age of our finished inventory to maximize the tradeoff between cash flow and profitability. Another focus has been to ‘right size’ our spec inventory at the community level to better align with community level demand.”

____________________

1 Backlog inventory consists of homes that are under a sales contract but have not closed. Backlog may be impacted by customer cancellations.

2 NM – Not Meaningful

About United Homes Group, Inc.

The Company is a publicly traded residential builder headquartered near Columbia, SC. The Company focuses on southeastern markets with active communities in South Carolina, North Carolina and Georgia.

The Company employs a land-light operating strategy with a focus on the design, construction and sale of entry-level, first, second and third move-up single-family houses. The Company principally builds detached single-family houses, and, to a lesser extent, attached single-family houses, including duplex houses and town houses. The Company seeks to operate its homebuilding business in high-growth markets, with substantial in-migrations and employment growth.

Under its land-light lot operating strategy, the Company controls its supply of finished building lots through lot option contracts with third parties, related parties, and land bank partners, which provide the Company with the right to purchase finished lots after they have been developed. This land-light operating strategy provides the Company with the ability to amass a pipeline of lots without the risks associated with acquiring and developing raw land.

As the Company reviews potential geographic markets into which it could expand its homebuilding business, it intends to focus on selecting markets with positive population and employment growth trends, favorable migration patterns, attractive housing affordability, low state and local income taxes, and desirable lifestyle and weather characteristics.

Forward-Looking Statements

Certain statements contained in this earnings release, other than historical facts, may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We intend for all such forward-looking statements to be covered by the applicable safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act, as applicable. Such forward-looking statements can generally be identified by our use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “seek,” “continue,” or other similar words.

Any such forward-looking statements are based on current expectations, estimates and projections about the industry and markets in which we operate, and beliefs of, and assumptions made by, our management and involve uncertainties that could significantly affect our financial results. Such statements include, but are not limited to, statements about our future financial performance, strategy, future operations, future operating results, plans and objectives of management. Such statements are subject to known and unknown risks and uncertainties, which could cause actual results to differ materially from those projected or anticipated, including, without limitation:

  • disruption in the terms or availability of mortgage financing or an increase in the number of foreclosures in our markets;
  • volatility and uncertainty in the credit markets and broader financial markets;
  • a slowdown in the homebuilding industry or changes in population growth rates in our markets;
  • shortages of, or increased prices for, labor, land or raw materials used in land development and housing construction, including due to changes in trade policies;
  • increases in interest rates or inflationary pressures;
  • our ability to execute our business model, including the success of our operations in new markets and our ability to expand into additional new markets;
  • our ability to successfully integrate homebuilding operations that we acquire;
  • our ability to realize the expected results of strategic initiatives;
  • delays in land development or home construction resulting from natural disasters, adverse weather conditions or other events outside our control;
  • changes in applicable laws or regulations;
  • the outcome of any legal proceedings;
  • our ability to continue to leverage our land-light operating strategy;
  • the ability to maintain the listing of our securities on Nasdaq or any other exchange; and
  • the possibility that we may be adversely affected by other economic, business or competitive factors.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and are not intended to be a guarantee of our performance in future periods. We cannot guarantee the accuracy of any such forward-looking statements contained in this release, and we do not intend to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

For further information regarding other risks and uncertainties associated with our business, and important factors that could cause our actual results to vary materially from those expressed or implied in such forward-looking statements, please refer to the factors listed and described under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the “Risk Factors” sections of the documents we file from time to time with the U.S. Securities and Exchange Commission, including, but not limited to, our Annual Report on Form 10-K and our quarterly reports on Form 10-Q, copies of which may be obtained from our website at https://ir.unitedhomesgroup.com/financials/sec-filings/default.aspx.

Investor Relations Contact:

Drew Mackintosh

[email protected]

Mobile: 310-924-9036

Media Contact:

Erin Reeves-McGinnis

[email protected]

Phone: 844-766-4663

KEYWORDS: United States North America South Carolina

INDUSTRY KEYWORDS: Residential Building & Real Estate Commercial Building & Real Estate Construction & Property

MEDIA:

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

– Mr. Ajer was most recently Chief Commercial Officer at BioMarin –

WALTHAM, Mass.–(BUSINESS WIRE)–
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors.

Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement, and sales operations. He most recently served as the Executive Vice President and Chief Commercial Officer (CCO) at BioMarin Pharmaceutical, where he joined in 2005 as one of the first sales and marketing employees and subsequently held roles of increasing responsibility that helped to establish BioMarin’s commercial infrastructure and global footprint. Mr. Ajer had direct responsibility for the launch of 5 brands during his time as CCO. Prior to BioMarin, Mr. Ajer served as Vice President, Global Transplant Operations at Genzyme Corporation and held positions in sales, marketing, and operations at SangStat Medical Corporation and ICN Pharmaceuticals. He received his B.S. degree in chemistry and M.B.A. from the University of California, Irvine.

“We are pleased to welcome Jeff to our Board of Directors at an exciting time for Viridian as we advance veligrotug, which we believe has a clinically differentiated profile, to BLA submission and, if approved, commercial launch,” said Steve Mahoney, President and Chief Executive Officer of Viridian Therapeutics. “Jeff’s extensive experience and expertise in commercial strategy and execution is a great addition to our Board as we continue to develop Viridian’s potential best-in-class assets across our thyroid eye disease and FcRn portfolios.”

Notice of Inducement Grants

Today, Viridian announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 220,750 shares of the company’s common stock to 14 new employees (the “Inducement Grants”) on April 1, 2025 (the “Grant Date”). The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to each employee’s continued employment with Viridian through the applicable vesting dates.

About Viridian Therapeutics

Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “will,” “could”, “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation the risks described from time to time in the “Risk Factors” section of our filings with the Securities and Exchange Commission (SEC), including those described in our most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as applicable, and supplemented from time to time by our Current Reports on Form 8-K. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Viridian believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Any forward-looking statement speaks only as of the date on which it was made. Neither Viridian, nor its affiliates, advisors, or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Viridian’s views as of any date subsequent to the date hereof.

Source: Viridian Therapeutics, Inc.

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Optical Health

MEDIA:

Logo
Logo

Bruker Introduces Innovative Fourier 80 Multinuclear Benchtop FT-NMR

Bruker Introduces Innovative Fourier 80 Multinuclear Benchtop FT-NMR

Unique Fourier 80 ‘Multi-Talent’ offers 1H NMR and choice of 15 X-nuclei with just one click

ASILOMAR, Calif.–(BUSINESS WIRE)–
At the Joint ENC-ISMAR Conference 2025, Bruker Corporation, the leading provider of Nuclear Magnetic Resonance (NMR) spectroscopy solutions, announced the launch of an innovative Fourier 80 multinuclear benchtop FT-NMR spectrometer, known as the ‘Multi-Talent’ configuration. This novel Fourier 80 ‘Multi-Talent’ system represents a major advancement in permanent magnet-based FT-NMR technology, as its unique, next-generation capabilities meet the evolving needs of academic researchers and industry scientists with dramatically enhanced versatility in benchtop FT-NMR multinuclear analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407545969/en/

Novel multinuclear benchtop Fourier 80 ‘Multi-Talent’ with optional sample changer automation

Novel multinuclear benchtop Fourier 80 ‘Multi-Talent’ with optional sample changer automation

The Fourier 80 ‘Multi-Talent’ system measures or decouples 1H, and in addition can select one of 15 different X-nuclei to be either observed in X{1H} experiments, or selected X-nuclei can be decoupled for proton observation in 1H{X} experiments. This enables many types of X-nucleus observations, various 2D experiments, and importantly also the exquisitely sensitive inverse 1H observation methods for 13C, 19F or 15N experiments.

Similarly, the Fourier 80 ‘Multi-Talent’ can observe 19F{1H} with proton decoupling for the simplification of 19F spectra, a capability of high interest to pharmaceutical customers studying fluorinated drug candidates. For battery research, the Fourier 80 ‘Multi-Talent’ enables nuclei observations from Li-brine mining, like 7Li, 23Na, and 11B for the formulation of battery electrolytes. Novel electrochemical systems can be explored to advance next generation battery technologies. These unprecedented benchtop capabilities are selectable via software, eliminating the need for NMR probe tuning and matching.

The ‘Multi-Talent’ uses standard 5 mm NMR samples, includes gradient spectroscopy, with options for adjustable sample temperature (AT), or sample changer automation. The user-friendly Fourier 80 interface ensures that novice and experienced users can navigate through measurements effortlessly, streamlining complex tasks and enhancing productivity.

Dr. Agnes Haber, the Fourier 80 Product Manager at Bruker BioSpin, stated: “The Fourier 80 ‘Multi-Talent’ represents a game-changing advancement in benchtop FT-NMR, with next-generation multinuclear capabilities addressing the demand for a versatile system for 1H-NMR, plus an unprecedented choice of fifteen X-nuclei, with ease, and even under automation. We have already successfully installed a dozen Fourier 80 multinuclear systems in customer labs, and we anticipate that this novel system may become the new de facto standard in benchtop multinuclear NMR spectroscopy.”

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Investor Contact:

Joe Kostka

Director – Investor Relations

Bruker Corporation

T: +1 (978) 313-5800

E: [email protected]

Media Contact:

Markus Ziegler

Sr. Director and Head of Group Marketing

Bruker BioSpin

T: +49 172 373-3531

E: [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology Technology Manufacturing Health Pharmaceutical Other Science Medical Devices Research Nanotechnology Engineering Science

MEDIA:

Photo
Photo
Novel multinuclear benchtop Fourier 80 ‘Multi-Talent’ with optional sample changer automation
Logo
Logo

Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims

PR Newswire


PITTSBURGH
, April 7, 2025 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS) (the “Company”) today announced it has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes against the Company and certain of its subsidiaries. While the Company’s presence in the U.S. opioids market is very small, the Company has agreed to this settlement to provide closure on these matters. This settlement is in no way an admission of wrongdoing or liability.

Under the agreed upon framework, depending on the level of participation in the settlement, the Company would pay up to a maximum of $335 million, consisting of annual payments over a nine-year period of between approximately $27.5 and $40 million each, to help support state and local efforts to address opioid-related issues. The Company had already accrued an estimate in respect of a potential settlement, which is reflected in the Company’s annual report on Form 10-K for the year ended December 31, 2024.  

The Company will also continue its longstanding role of working to identify solutions to address pressing public health challenges like those relating to opioids. For example, the Company manufactures a generic injectable version of the life-saving overdose reversal drug, naloxone, as well as a generic buprenorphine/naloxone product used for the treatment of opioid addiction. The Company is also developing a novel delivery for meloxicam, a non-opioid pain medication.

The settlement enables the Company to further focus on its mission of empowering people worldwide to live healthier at every stage of life, advance its efforts to address unmet patient needs through an expanded innovative portfolio and continue to serve approximately 1 billion patients annually with its diverse portfolio of medicines.

About Viatris
Viatris Inc
. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life’s moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedInInstagramYouTube and X (formerly Twitter).

Forward-Looking Statements

This press release includes statements that constitute “forward-looking statements.” These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements regarding the Company’s nationwide settlement framework to resolve opioid-related claims by states, local governments, and Tribes against the Company and certain of its subsidiaries; under the agreed upon framework, depending on the level of participation in the settlement, the Company would pay up to a maximum of $335 million, consisting of annual payments over a nine-year period of between approximately $27.5 and $40 million each, to help support state and local efforts to address opioid-related issues; that the Company will also continue its longstanding role of working to identify solutions to address pressing public health challenges like those relating to opioids; the Company is also developing a novel delivery for meloxicam, a non-opioid pain medication; and that the settlement enables the Company to further focus on its mission of empowering people worldwide to live healthier at every stage of life, advance its efforts to address unmet patient needs through an expanded innovative portfolio and continue to serve approximately 1 billion patients annually with its diverse portfolio of medicines. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the inability or unwillingness on the part of any of the parties to agree to a final settlement; any legal or regulatory challenges to the settlement; the level of participation by litigants or claimants in the settlement framework; any failure by third parties to comply with their contractual obligations; actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris’ ability to bring new products to market; Viatris’ or its partners’ ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris’ failure to achieve expected or targeted future financial and operating performance and results; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris’ or its partners’ customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, tariffs and trade policies, inflation rates and global exchange rates; and the other risks described in Viatris’ filings with the Securities and Exchange Commission (“SEC”). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-statement-on-nationwide-settlement-to-resolve-opioid-related-claims-302421642.html

SOURCE Viatris Inc.

Republic Airways and Mesa Air Group to Combine, Creating America’s Regional Airline of Choice

PR Newswire

Brings together two highly complementary cultures, fleets, and operations, which will continue to connect communities across America


CARMEL, Ind. and PHOENIX
, April 7, 2025 /PRNewswire/ — Republic Airways Holdings Inc. and Mesa Air Group, Inc. (NASDAQ: MESA) today announced that they have entered into a definitive agreement to merge and create a leading publicly-traded regional airline company in an all-stock transaction. Upon closing, the combined company will be renamed Republic Airways Holdings Inc. and is expected to remain NASDAQ-listed under the new ticker symbol “RJET”.

“Today’s announcement is an exciting next step in Mesa’s more than 40-year history, one that represents the best outcome for our shareholders, employees, and all of our stakeholders,” said Jonathan Ornstein, Mesa’s Chairman and Chief Executive Officer. “By bringing the best of our organizations together, we will create a regional carrier that continues to connect communities across America while providing advancement opportunities to our employees.”

“We’re thrilled to combine the Republic and Mesa teams to create one of the world’s leading Embraer Jet operators,” said Bryan Bedford, Republic’s President and Chief Executive Officer. “Republic and Mesa share a common mission to connect communities across America, and we believe that we can better achieve that mission together. With this combination, we are establishing a single, well-capitalized, public company that will benefit from the deep expertise of Republic and Mesa associates, creating value for all stakeholders well into the future.”

Republic Airways Overview

Republic Airways has been a leading regional airline since its inception in 1974 and is now one of the largest regional airlines in the United States. Republic has a fleet of more than 240 Embraer 170/175 aircraft and carried approximately 17.5 million passengers on more than 300,000 flights and 591,000 block hours in 2024. The airline primarily serves Northeast and Mid-Atlantic hubs and operates exclusively under long-term capacity purchase agreements with American Airlines, Delta Air Lines and United Airlines. In 2024, Republic delivered strong financial performance, producing net income of approximately $65 million on total revenues of approximately $1.5 billion. During the year then ended, Republic generated total operating expenses of approximately $1.3 billion, of which approximately $117 million is non-cash depreciation and amortization expense, other net non-operating expenses (primarily interest expense) of approximately $50 million, and income tax expense of approximately $22 million, resulting in EBITDA performance of approximately $254 million and pre-tax income of approximately $87 million. As of December 31, 2024, Republic’s cash and debt balances were $323 million and $1 billion, respectively, resulting in net leverage of approximately 2.7x. Republic expects to take delivery of 15 new E175 aircraft during 2025 and all of the deliveries are expected to be debt financed.

Compelling Strategic Rationale

  • Economies of Scale: The proposed combination represents a transformational opportunity to significantly enhance the scale of the combined airlines, both financially, and operationally, with a larger, unified fleet. This will enable more efficient and productive regional flying and crew resource management. The enhanced platform is well positioned for a valuation uplift, supported by a stronger financial profile, increased relevance among global institutional investors, and improved access to capital markets.

  • Enhanced Capital and Liquidity Position: Pro forma net leverage at close is expected to be approximately 2.5x and liquidity as a percent of pro forma revenues is expected to be greater than 15%. Together, the combined company will have the financial strength and flexibility to make critical investments, drive sustained profitability, and continue delivering best-in-class customer service under a unified brand. A stronger balance sheet for the combined airline will bolster the Company’s ability to navigate market cycles, respond to strategic opportunities, and maintain a flexible capital allocation strategy that optimizes returns for all stakeholders.

  • Complementary Networks and Operations: The proposed combination represents a unique opportunity to bring together Mesa’s and Republic’s networks to establish America’s regional airline of choice. The post-merger company will maintain a single fleet of approximately 310 Embraer 170/175 (“E-Jet”) aircraft, with over 1,250 daily departures, across both airlines’ existing flying networks and will operate within Mesa’s and Republic’s current basing structures and routes. Mesa and Republic will continue to operate under their existing Federal Aviation Administration (FAA) operating certificates until securing a single-operating certificate for the combined airline.

  • Synergistic Cultures Rooted in Safety and Reliability: Mesa and Republic share common values and principles, which include an uncompromising focus on providing safe and reliable services for passengers, operational excellence, and a culture which provides career growth and advancement opportunities for associates. Both Mesa and Republic are included in the International Air Transport Association’s Operational Safety Audit (IOSA) registry, the internationally recognized standard for airline safety and operational excellence. These principles will be maintained and enhanced by the merger.

  • Talented Team Positioned for Exciting Growth Opportunities: The combined company will continue serving key partners, including American Airlines, Delta Air Lines, and United Airlines. The parties expect to retain all flight crews, technicians, and other operational staff within the post-merger entity, which will be led by an experienced and seasoned management team.

Overview of the Combined Company:

Republic will continue to support American Airlines, Delta Air Lines, and United Airlines under its existing capacity purchase agreements (“CPA”), and Mesa’s operations will support United Airlines under a new 10-year CPA, as a result of this transaction. The combined company is expected to produce revenues of approximately $1.9 billion, pretax margins of 7% to 9%, excluding one-time merger and integration costs, and adjusted EBITDA in excess of $320 million. As part of the transaction, Mesa will not contribute any debt to the combined airline. The pro forma cash and debt balances post-merger are forecasted to be $285 million and $1.1 billion, respectively. The transaction is anticipated to deliver value creation for both Mesa and Republic shareholders, who stand to benefit from the ownership of a better capitalized airline with increased economies of scale, due to Republic’s strong financial position, stable earnings and cash flow.

Management and Governance

The combined company will be led by Republic’s executive leadership team. The Board of Directors will be comprised of six existing directors from the Republic Board of Directors and one independent director from the Mesa Board of Directors.

Transaction Details and Conditions to Close

Upon closing of the transaction, Republic shareholders will own 88% of the combined company’s common shares. Mesa shareholders will own a minimum of 6%, and up to 12% of the combined company dependent upon Mesa’s achievement of certain pre-closing criteria. All outstanding Mesa debt obligations will be extinguished as a result of the transaction.

Concurrently with the execution and delivery of the Merger Agreement, Mesa, Republic and United Airlines, Inc. (“United”), among other parties, entered into a Three Party Agreement (the “Three Party Agreement”), pursuant to which, among other things: (i) Mesa will take certain actions at or prior to the closing of the Merger to dispose of certain assets, extinguish certain liabilities and effectuate certain related transactions; and (ii) United will take certain actions at or prior to the closing of the Merger to facilitate Mesa’s actions in the foregoing clause (i).

The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in either the late third or early fourth quarter of 2025. The transaction is subject to customary closing conditions, including regulatory and shareholder approvals by both companies.

Advisors

Simpson Thacher & Bartlett LLP is serving as legal counsel and Goldman Sachs & Co. LLC is serving as financial advisor to Republic Airways.

FTI Capital Advisors, LLC is serving as financial advisor to Mesa Air Group. Pachulski Stang Ziehl & Jones LLP and DLA Piper LLP are serving as legal counsel.

Sidley Austin LLP is serving as legal counsel to United.

About Republic Airways Inc.

Founded in 1974, Republic Airways maintains a fleet of more than 240 Embraer 170/175 aircraft and offers scheduled passenger service with more than 1,000 daily scheduled flights to more than 80 cities in the U.S., Canada, the Caribbean and Central America. The airline provides fixed-fee flights operated under its codeshare partners’ brands: American Eagle, Delta Connection and United Express. The airline employs more than 6,000 aviation professionals. Learn more at www.rjet.com.

About Mesa Air Group, Inc.

Founded in 1982 and headquartered in Phoenix, Arizona, Mesa Air Group, Inc. is the holding company of Mesa Airlines, a regional air carrier providing scheduled passenger service to 89 cities in 40 states, the District of Columbia, the Bahamas, Canada, Cuba, and Mexico. Mesa operates a fleet of 60 Embraer 175 aircraft with more than 250 daily scheduled departures and has approximately 1,700 employees. Mesa operates all its flights as United Express pursuant to the terms of a capacity purchase agreement entered into with United Airlines, Inc. Learn more at www.mesa-air.com

Forward-Looking Statements
This press release may be deemed to contain forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding the effects of the restatement of Mesa’s past financial statements and the filing of Mesa’s amended periodic reports. Words such as “future,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “may,” “might,” “predict,” “will,” “would,” “should,” “could,” “can,” “may,” or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements.

The forward-looking statements contained in this press release reflect Mesa’s current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances, many of which are beyond the control of Mesa, that may cause actual results and future events to differ significantly from those expressed in any forward-looking statement, which risks and uncertainties include, but are not limited to: the ability to complete the proposed transaction on the proposed terms or on the anticipated timeline, or at all, including risks and uncertainties related to securing the necessary stockholder approval and satisfaction of other closing conditions to consummate the proposed transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement relating to the proposed transaction; risks that the proposed transaction disrupts Mesa’s current plans and operations or diverts the attention of Mesa’s management or employees from ongoing business operations; the risk of potential difficulties with Mesa’s ability to retain and hire key personnel and maintain relationships with customers and other third parties as a result of the proposed transaction; the failure to realize the expected benefits of the proposed transaction; the risk that the proposed transaction may involve unexpected costs and/or unknown or inestimable liabilities; the risk that Mesa’s business may suffer as a result of uncertainty surrounding the proposed transaction; the risk that stockholder litigation in connection with the proposed transaction may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification and liability; effects relating to the announcement of the transaction or any further announcements or the consummation of the transaction on the market price of Mesa Common Stock.

While forward-looking statements reflect Mesa’s good faith beliefs, they are not guarantees of future performance or events. Any forward-looking statement speaks only as of the date on which it was made. Mesa disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes. For a further discussion of these and other factors that could cause Mesa’s future results to differ materially from any forward-looking statements, see the section entitled “Risk Factors” in Mesa’s Annual Report on Form 10-K for the year ended September 30, 2023, filed with the SEC on January 26, 2024, as amended by Form 10-K/A filed with the SEC on February 27, 2024, as updated by Mesa’s subsequent periodic reports filed with the SEC.

Additional Information and Where to Find It
This press release relates to the proposed merger involving Mesa and Republic. In connection with the proposed transaction, Mesa will file with the SEC a Form S-4 Registration Statement, which will include a proxy statement on Schedule 14A. Promptly after filing its definitive proxy statement with the SEC, Mesa will mail the definitive proxy statement and a proxy card to each stockholder entitled to vote at the special meeting relating to the proposed transaction. INVESTORS AND SECURITY HOLDERS OF MESA ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT MESA FILES WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. The definitive proxy statement, the preliminary proxy statement and any other documents filed by Mesa with the SEC (when available) may be obtained free of charge at the SEC’s website at www.sec.gov or by accessing the Investor Relations section of Mesa’s website at https://investor.mesa-air.com/.

Information Regarding Non-GAAP Financial Measures
This communication contains certain information that is not calculated according to GAAP (“non-GAAP”), such as EBITDA, Adjusted EBITDA and Net Leverage. We believe that investors will find these non-GAAP measures useful in evaluating our performance. These measures are frequently used by security analysts, institutional investors and other interested parties in the evaluation of companies in our industry. Non-GAAP measures should not be considered in isolation or as a substitute for our reported results prepared in accordance with GAAP and, as calculated, may not be comparable to similarly titled measures of other companies. Lastly, this communication also includes certain forward-looking non-GAAP financial measures. We are unable to present a quantitative reconciliation of this forward-looking non-GAAP financial information because management cannot reliably predict all of the necessary components of such measures.

Media Contacts 

For Republic Airways
(612) 839-5172
[email protected]

Danielle Fornabaio / Ashley Grund of Gladstone Place Partners
212-230-5930

For Mesa Air Group
(602) 685 4010
[email protected]

 

Cision View original content:https://www.prnewswire.com/news-releases/republic-airways-and-mesa-air-group-to-combine-creating-americas-regional-airline-of-choice-302421902.html

SOURCE Republic Airways Inc.; Mesa Air Group, Inc.

Talos Energy to Announce First Quarter 2025 Results on May 5, 2025 and Host Earnings Conference Call on May 6, 2025

PR Newswire


HOUSTON
, April 7, 2025 /PRNewswire/ — Talos Energy Inc. (“Talos” or the “Company”) (NYSE: TALO) intends to release first quarter 2025 results for the period ended March 31, 2025, on Monday, May 5, 2025, after the U.S. financial market closes. In addition to this release, Talos will host a conference call, broadcast live over the internet, on Tuesday, May 6, 2025, at 10:00 AM Eastern Time (9:00 AM Central Time).

Listeners can access the conference call through a webcast link on the Company’s website at: https://www.talosenergy.com/investor-relations/presentation-webcast/default.aspx#event-calendar. Alternatively, the conference call can be accessed by dialing (800) 836-8184 (North American toll-free) or (646) 357-8785 (international). Please dial in approximately 15 minutes before the teleconference is scheduled to begin and ask to be joined into the Talos Energy call. A replay of the call will be available one hour after the conclusion of the conference until May 13, 2025 and can be accessed by dialing (888) 660-6345 and using access code 14247#.

ABOUT TALOS ENERGY

Talos Energy (NYSE: TALO) is a technically driven, innovative, independent energy company focused on maximizing long-term value through its Exploration & Production business in the United States Gulf of America and offshore Mexico. We leverage decades of technical and offshore operational expertise to acquire, explore, and produce assets in key geological trends while maintaining a focus on safe and efficient operations, environmental responsibility, and community impact. For more information, visit

www.talosenergy.com

.

INVESTOR RELATIONS CONTACT

Clay Jeansonne

[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/talos-energy-to-announce-first-quarter-2025-results-on-may-5-2025-and-host-earnings-conference-call-on-may-6-2025-302421309.html

SOURCE Talos Energy

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

  • Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelines
  • Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in 2H2026
  • Orphan medicinal product designation granted to deucrictibant in Europe for the treatment of bradykinin-mediated angioedema
  • Data presented at recent congresses reinforces the value of deucrictibant by highlighting its ability to maintain a reduced attack rate in long-term prophylaxis, and potential to rapidly and completely treat HAE attacks, including in participants experiencing upper-airway attacks
  • Strong financial position with cash and cash equivalents of €281 million as of December 31, 2024

ZUG, Switzerland, April 07, 2025 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.

“Pharvaris is focused on the development of deucrictibant to address unmet needs for people living with bradykinin-mediated angioedema; our priority remains generating robust clinical data to support this goal. We are pleased to have met our aggressive enrollment timelines for RAPIDe-3; we believe this was driven by high engagement from the HAE community, reinforcing the excitement about the clinical data and the potential impact of deucrictibant for those with bradykinin-mediated angioedema,” said Berndt Modig, Chief Executive Officer of Pharvaris. “To our knowledge, deucrictibant is the only orally-administered bradykinin B2 receptor antagonist in development for both the prophylactic and on-demand treatment of bradykinin-mediated angioedema. Consistent with the U.S. Food and Drug Administration, the European Commission’s granting of orphan designation to deucrictibant reiterates its potential to address unmet medical needs in HAE, as well as other bradykinin-mediated angioedema diseases.”

Recent Business Updates

Development Pipeline

  • Target enrollment achieved in RAPIDe-3 (

    NCT06343779

    ). RAPIDe-3, a pivotal global Phase 3 study evaluating deucrictibant immediate-release capsule (20 mg) for the on-demand treatment of HAE attacks in adults and adolescents (12 years and older), has reached its target enrollment and continues to assess HAE attacks in approximately 120 participants.
  • Enrollment in CHAPTER-3 (

    NCT06669754

    ) progressing as planned. CHAPTER-3 is a randomized, double-blind, placebo-controlled Phase 3 study of orally administered deucrictibant extended-release tablet for the prophylaxis against angioedema attacks in adults and adolescents (12 years and older) with HAE. The study aims to enroll approximately 81 participants with HAE and randomize them in a 2:1 ratio to receive deucrictibant extended-release tablet (40 mg/day), which is the intended commercial dosage, or placebo, once daily for 24 weeks. Pharvaris anticipates announcing topline data of CHAPTER-3 in the second half of 2026.
  • Open-label extensions of deucrictibant in both prophylaxis (CHAPTER-4,

    NCT06679881

    ) and on-demand (RAPIDe-2,

    NCT05396105

    ) are ongoing. Participants who have completed the randomized clinical trials for the prophylactic or on-demand treatment of HAE attacks with deucrictibant are eligible to continue deucrictibant therapy through open-label extension studies. The intention of the studies is to evaluate the long-term safety and efficacy of deucrictibant for the prevention or treatment of HAE attacks.
  • Data presentations at recent congresses highlight long-term clinical data of deucrictibant. Recent presentations at the Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 Annual Meeting, the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress, and the 2025 HAE International (HAEi) Regional Conference APAC, support Pharvaris’ deucrictibant product strategy. Long-term extension data from the open-label extension (OLE) part of CHAPTER-1 study showed that deucrictibant maintained the reduced monthly HAE attack rate for at least a year and a half, and the median proportion of days with symptoms during the OLE was further reduced to zero days. The ongoing RAPIDe-2 extension study includes efficacy data from seven upper airway, including laryngeal, attacks, in which the median time to onset of symptom relief was 0.9 hours (N=7).

Corporate

  • Orphan designation granted to deucrictibant for the treatment of bradykinin-mediated angioedema. On March 28, 2025, the European Commission (EC) granted orphan designation to deucrictibant for the treatment of bradykinin-mediated angioedema in the European Union. The U.S. Food and Drug Administration (FDA) previously granted orphan drug designation to deucrictibant for the treatment of bradykinin-mediated angioedema in March 2022.

Upcoming Investor Events

  • The Citizens JMP Life Sciences Conference, New York, New York, May 7-8, 2025
    Format:  Fireside Chat
    Date, time: Thursday, May 8, 12:30 p.m. ET
  • Bank of America Global Healthcare Conference, Las Vegas, Nevada, May 13-15, 2025
    Format:  Company Presentation
    Date, time: 8:40-8:55 a.m. PT (11:40-11:55 a.m. ET)

Live audio webcasts will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. The audio replays will be available on Pharvaris’ website for 30 days following the events.

Financials

Fourth Quarter and Full Year 2024 Financial Results

  • Liquidity Position. Cash and cash equivalents were €281 million as of December 31, 2024, compared to €391 million for December 31, 2023.
  • Research and Development (R&D) Expenses. R&D expenses were €31.2 million for the fourth quarter and €98.6 million for the full year of 2024, compared to €18.6 million for the fourth quarter and €65.6 million for the full year of 2023.
  • General and Administrative (G&A) Expenses. G&A expenses were €13.9 million for the fourth quarter and €47.1 million for the full year of 2024, compared to €8.6 million for the fourth quarter and €31.3 million for the full year of 2023.
  • Loss for the year. Loss for the fourth quarter of 2024 was €34.8 million, resulting in basic and diluted loss per share of €0.64. For the full year of 2024, loss was €134 million, resulting in basic and diluted loss per share of €2.48 per share. This compares to €32.7 million, or basic and diluted loss per share of €0.95, for the fourth quarter of 2023 and €100.9 million, or basic and diluted loss per share of €2.63, for the full year of 2023.

Note on International Financial Reporting Standards (IFRS)

Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board. Pharvaris maintains its books and records in the Euro currency.

About Deucrictibant

Deucrictibant is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist currently in clinical development. By inhibiting bradykinin signaling through the bradykinin B2 receptor, deucrictibant is being investigated for its potential to prevent the occurrence of bradykinin-mediated angioedema attacks and to treat the manifestations of attacks if/when they occur. Based on its chemical properties, Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy as prophylactic treatment, and an immediate-release capsule to enable rapid onset of activity for on-demand treatment. Deucrictibant has been granted orphan drug designation by the U.S. Food and Drug Administration and orphan designation by the European Commission.

About Pharvaris

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.

Forward Looking Statements

This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words “believe,” “anticipate,” “expect,” “estimate,” “may,” “could,” “should,” “would,” “will,” “intend” and similar expressions. These forward-looking statements are based on management’s current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris’ actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA; the expected timing, progress, or success of our clinical development programs, especially for deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials; our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, and CHAPTER-1 Phase 2 and Phase 3 studies in ongoing and future nonclinical studies and clinical trials; risks arising from epidemic diseases, , which may adversely impact our business, nonclinical studies, and clinical trials; our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH); the outcome and timing of regulatory approvals; the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to produce sufficient amounts of drug product candidates for commercialization; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws (including the Biosecure Act), our ability to successfully remediate the material weaknesses in our internal control over financial reporting and to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market, political and economic conditions, including as a result of inflation and the current conflict between Russia and Ukraine and the Hamas attack against Israel and the ensuing war; and the other factors described under the headings “Cautionary Statement Regarding Forward-Looking Statements” and “Item 3. Key Information—D. Risk Factors” in our Annual Report on Form 20-F and other periodic filings with the U.S. Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris’ views as of any date subsequent to the date of this press release.



Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
[email protected]